Clinical trial
A Multi-Modular Trial to Evaluate VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease and Other Bleeding Disorders (VIVID)
NCT05776069 is registered in ClinicalTrials.gov with Vega Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Modular Trial to Evaluate VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease and Other Bleeding Disorders (VIVID)
- Lead sponsor
- Vega Therapeutics, Inc
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 16, 2023
- Completion date
- December 31, 2029
- Enrollment
- 116 (estimated)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.